Latest news with #CorceptTherapeutics
Yahoo
11 hours ago
- Business
- Yahoo
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the . Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company specializing in cortisol modulation by developing compounds that antagonize the glucocorticoid receptor. Based in California, the company treats Cushing's syndrome with its commercial drug Korlym. The company advances a pipeline of over 30 clinical-stage molecules for endocrinology, oncology, metabolism, and neurology. On July 14, 2025, the company announced that it had filed for a new drug application to the U.S. FDA for relacorilant. Relacorilant is a selective cortisol modulator for treating platinum-resistant ovarian cancer. The submission follows the positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. The trials indicated that relacorilant combined with nab-paclitaxel offers improved progression-free and overall survival, without increasing the safety burden of the patients. Since platinum-resistant ovarian cancer currently has limited therapies, the FDA approval for relacorilant has high expectations. Amid this advancement in Corcept Therapeutics Incorporated (NASDAQ:CORT)'s relacorilant, Piper Sandler and H.C. Wainwright reiterated their Buy rating on the stock. Piper Sandler maintains a price target of $131 while H.C. Wainwright has set the price target at $145. With an impressive projected 5-year EPS growth of 69.48% and a low beta of 0.21, Corcept Therapeutics Incorporated (NASDAQ:CORT) promises an attractive investment for those seeking high growth at low risk. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-07-2025
- Business
- Business Insider
Piper Sandler pharmaceuticals analyst holds analyst/industry conference call
Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)' Relacorilant in ovarian cancer on an Analyst/Industry conference call to be held on July 10. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
07-07-2025
- Business
- Yahoo
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 2, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced pivotal data from its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the American Society of Clinical Oncology Annual Meeting. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. According to the release, ROSELLA met its primary endpoint of improved progression-free survival according to assessment by blinded independent central review (PFS-BICR). A 30% reduction in disease progression risk was recorded in patients who received relacorilant in addition to nab-paclitaxel chemotherapy as compared to those who received nab-paclitaxel monotherapy only. The results also showed that relacorilant plus nab-paclitaxel was well-tolerated and exhibited a comparable safety profile between treatment arms. Adding relacorilant did not cause a rise in patients' safety burden. In fact, patients who were administered relacorilant plus nab-paclitaxel experienced a lower incidence of ascites (5.3%) compared to those who received nab-paclitaxel alone (10.5%). The occurrence of abdominal paracenteses during treatment was also lower for the former patients. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company's flagship product, Korlym, is FDA-approved for the treatment of Cushing's syndrome, a disorder characterized by excessive cortisol production. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
04-07-2025
- Business
- Yahoo
Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best NASDAQ growth stocks to buy for the next 3 years. On June 24, Corcept Therapeutics announced positive results from the CATALYST trial of Korlym (mifepristone). The data was presented at the American Diabetes Association's 85th Scientific Sessions and also published in Diabetes Care. It showed that Korlym improved glucose control in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. The trial met its primary endpoint, as patients receiving Korlym experienced a 1.47% decrease in HbA1c from baseline, as compared to a 0.15% decrease in the placebo group. Those on a 900mg dose saw a 2.01% HbA1c improvement. Beyond blood sugar, Korlym also led to reductions in body weight (by 5.1 kg) and waist circumference (by 5.1 cm), even as patients reduced or stopped other glucose-lowering medications. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. The CATALYST trial is the largest to date investigating hypercortisolism in difficult-to-control type 2 diabetes. Its initial phase screened 1,057 patients and found that 24% had hypercortisolism, which made them eligible for the treatment phase. Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Globe and Mail
02-07-2025
- Business
- Globe and Mail
Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players
DelveInsight's, 'Adrenocortical Carcinoma Pipeline Insight 2025' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook Key Takeaways from the Adrenocortical Carcinoma Pipeline Report In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment. DelveInsight's Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment. The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others. Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others. Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs Adrenocortical Carcinoma Emerging Drugs Profile Relacorilant: Corcept Therapeutics Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer. Ipilimumab: Bristol-Myers Squibb Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma. The Adrenocortical Carcinoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment. Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adrenocortical Carcinoma Drugs Adrenocortical Carcinoma Companies Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others. Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Adrenocortical Carcinoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers Scope of the Adrenocortical Carcinoma Market Report Coverage- Global Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others. Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others. Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Adrenocortical Carcinoma: Overview Pipeline Therapeutics Therapeutic Assessment Adrenocortical Carcinoma– DelveInsight's Analytical Perspective Mid Stage Products (Phase II) Ipilimumab: Bristol-Myers Squibb Drug profiles in the detailed report….. Early Stage Products (Phase I) Relacorilant: Corcept Therapeutics Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Adrenocortical Carcinoma Key Companies Adrenocortical Carcinoma Key Products Adrenocortical Carcinoma- Unmet Needs Adrenocortical Carcinoma- Market Drivers and Barriers Adrenocortical Carcinoma- Future Perspectives and Conclusion Adrenocortical Carcinoma Analyst Views Adrenocortical Carcinoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
